Business Context and Reporting Period
Company: Oragenics, Inc. (OGEN)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Oragenics is a development-stage biopharmaceutical company focused on nasal delivery therapies for neurological conditions. Its primary asset is ONP-002, a synthetic neurosteroid in development for the treatment of mild traumatic brain injury (mTBI/concussion). The company has no approved products for commercial sale and has incurred significant losses since inception.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(9.84) million | $(10.57) million |
| Operating Expenses | $9.36 million | $10.56 million |
| Cash and Cash Equivalents (Year End) | $4.40 million | $0.86 million |
| Total Assets | $10.07 million | $1.47 million |
| Accumulated Deficit | $(226.63) million | $(216.79) million |
| Short-Term Debt | $0.23 million | $0.33 million |
Note: The company holds $4.0 million in short-term investments as of December 31, 2025.
Material Changes vs. Prior Period
- Financing Activities: The company significantly improved its liquidity position in 2025 through a July 2025 public offering of Series H Convertible Preferred Stock and warrants, raising approximately $15.2 million in net proceeds. Additionally, the company raised $2.6 million via an At-The-Market (ATM) agreement and $2.2 million via a promissory note (which was repaid in July 2025).
- Operating Expenses: Total operating expenses decreased by 11.3% to $9.36 million. Research and Development (R&D) expenses dropped 41.9% to $2.39 million due to the wind-down of discontinued vaccine and antibiotic programs and a strategic focus on ONP-002. General and Administrative (G&A) expenses increased 8.1% to $6.97 million, driven by higher patent costs and investor relations expenses.
- Capital Structure: A 1-for-30 reverse stock split was effected on June 3, 2025. The company issued 660,000 shares of Series H Preferred Stock and 429,291 shares remained outstanding at year-end. Series F Preferred Stock remains outstanding but is subject to conversion conditions.
- Legal Settlement: The company settled a dispute with Ladenburg Thalmann & Co. Inc. regarding an investment banking fee, agreeing to pay $700,000 in October 2025.
Guidance, Outlook, and Risks
Outlook and Guidance
- Cash Runway: Management estimates that current cash resources ($8.4 million including short-term investments) will fund operations through the third quarter of 2026.
- Development Timeline:
- Phase 2a Clinical Trial: Anticipated to start in Q1 2026 in Australia.
- US-Based Clinical Trial (Phase 2b): Estimated start in Q1 2027.
- Phase 3 Clinical Trial: Estimated start in Q1 2028.
- Capital Needs: The company explicitly states it will require additional capital to complete the development of ONP-002 and operate beyond Q3 2026. Future funding may come from equity offerings, debt, or strategic partnerships.
Risks and Contingencies
- Going Concern: The independent auditor has included an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
- Dilution Risk: The Series H Preferred Stock contains anti-dilution provisions. If the company issues securities below the conversion price, the conversion price will be lowered, potentially resulting in significant dilution. The conversion price was recently reduced to $1.00 per share.
- Regulatory Approval: There is no guarantee that ONP-002 will receive FDA or other regulatory approvals. Clinical trials may fail, be delayed, or reveal safety issues.
- Listing Compliance: While currently compliant with NYSE American listing standards, the company faces risks of delisting if it cannot maintain compliance in the future.
Investor Verification Checklist
- Liquidity Horizon: Verify the company's ability to raise capital before Q3 2026 to avoid operational curtailment.
- Series H Terms: Review the specific anti-dilution mechanics of the Series H Preferred Stock and the impact of the recent conversion price reduction to $1.00.
- Clinical Milestones: Monitor the initiation of the Phase 2a trial in Q1 2026 and the subsequent data readouts.
- Legal Exposure: Confirm that the $700,000 settlement with Ladenburg Thalmann fully resolves all related claims.
- Patent Portfolio: Assess the status of the C-20 steroid compound patents and the Breath-Powered Nasal Device patents, noting expiration dates (2035-2042).